The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.45 which represents a decrease of $-0.89 or -1.04% from the prior close of $85.34. The stock opened at $84.87 and touched a low of $84 ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
The Novo Nordisk Foundation continues to prioritize its focus on non-communicable diseases despite a global health crisis prompted by the U.S. freeze on foreign aid. With substantial assets, the ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
SAN DIEGO, CA / ACCESS Newswire / January 31, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all investors ...
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...